Transient Effect of the Combination of Insulin and Sulfonylurea (Glibenclamide) on Glycemic Control in Non-Insulin Dependent Diabetics Poorly Controlled with Insulin Alone-Reference-Cited by-同舟云学术

Transient Effect of the Combination of Insulin and Sulfonylurea (Glibenclamide) on Glycemic Control in Non-Insulin Dependent Diabetics Poorly Controlled with Insulin Alone

Published:2009-04-24 Issue:1 Volume:217 Page:33-39
ISSN:0001-6101
Container-title:Acta Medica Scandinavica
language:en
Short-container-title:

Author:

GROOP L.,HARNO K.,NIKKILÄ E. A.,PELKONEN R.,TOLPPANEN E.-M.

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.0954-6820.1985.tb01631.x/fullpdf

Reference27 articles.

1. Ineffectiveness of sulfonylureas in alloxan diabetic rats;Mirsky;Proc Soc Exp Biol Med,1956

2. Appraisal of the extrapancreatic actions of sulfonylureas;Feldman;Arch Intern Med,1969

3. New concepts in the pathogenesis and tretment of non-insulin dependent diabetes mellitus;DeFronzo;Am J Med,1983

4. Hepatic effects of sulfonylureas;Marshall;Metabolism,1970

5. Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide;Beck-Nielsen;Acta Endocrinol,1979

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review;International Journal of Endocrinology and Metabolism;2018-04-21

2. The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes;Mayo Clinic Proceedings;2018-02

3. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control;Cochrane Database of Systematic Reviews;2016-09-18

4. Glibenclamide Improves the Response to Insulin Treatment in Non-insulin-dependent Diabetics with Second Failure to Sulfonylurea Therapy;Acta Medica Scandinavica;2009-04-24

5. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes;Diabetes/Metabolism Research and Reviews;2007